News
As America grapples with one of the worst flu outbreaks in recent years, researchers are hoping to close in on a stronger ...
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
U.S. Health Secretary Robert F. Kennedy Jr’s newly appointed Advisory Committee on Immunization Practices (ACIP) upheld ...
16h
Bizcommunity on MSNSouth Africa issues first permit for avian influenza vaccinationThe Department of Agriculture has issued its first-ever permit to vaccinate poultry against highly pathogenic avian influenza ...
Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results